Supernus Announces First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 6, 2025
ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2025 and associated Company developments.
Read more at globenewswire.com
